2006年4月
Ex vivo CD4+ T-cell cytokine expression from patients with Sjogren's syndrome following in vitro stimulation to induce proliferation
RHEUMATOLOGY
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 45
- 号
- 4
- 開始ページ
- 392
- 終了ページ
- 399
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1093/rheumatology/kei182
- 出版者・発行元
- OXFORD UNIV PRESS
Objective. To assess ex vivo CD4+ T-cell cytokine expression from patients with primary Sjogren's syndrome (SS) following in vitro stimulation to induce proliferation, as proliferation is closely related to differentiation of cytokine-producing cells.
Methods. Peripheral blood mononuclear cells (PBMCs) separated from primary SS patients (n = 28) and controls (n = 25) were analysed. PBMCs were stimulated with concanavalin A followed by phorbol 12-myristate 13-acetate and ionomycin. Intracellular interferon-gamma (IFN-gamma) and interleukin-4 (IL)-4 in proliferating CD4+ T cells were assessed by flow cytometry. The proportion of cytokine-producing cells and proliferating cells in each division cycle was assessed using [5(and 6)-carboxyfluorescein diacetate, succinimidyl ester]-labelled CD4 +/- T cells.
Results. The proportion of IFN-gamma+ proliferating CD4+ T cells in each cell division cycle from extraglandular SS was increased in glandular SS patients compared glandular SS patients with controls (P < 0.05 similar to 0.01). The percentage of IFN-gamma single positive proliferating CD4+ T cells was greater in extraglandular SS patients (26.7 +/- 14.1%) compared with glandular SS (9.9 +/- 9.1%) (P < 0.01) and controls (9.4 +/- 5.8%) (P < 0.001). There was no significant difference in the percentages of IL-4+ proliferating CD4+ T cells among the groups. However, the proliferating response of CD4+ T cells was significantly decreased in extraglandular SS patients (percentage of proliferating cells 38.4 +/- 18.6%) compared with that in glandular SS patients (64.2 +/- 17.2%) (P < 0.05) and controls (63.1 +/- 10.6%) (P < 0.01).
Conclusions. CD4+ T cells from extraglandular SS patients may have a predisposition for entry into the IFN-gamma-producing effector pathway as a result of the stimulations. These results are helpful for understanding the immunological difference between glandular and extraglandular SS and the mechanisms of disease progression.
Methods. Peripheral blood mononuclear cells (PBMCs) separated from primary SS patients (n = 28) and controls (n = 25) were analysed. PBMCs were stimulated with concanavalin A followed by phorbol 12-myristate 13-acetate and ionomycin. Intracellular interferon-gamma (IFN-gamma) and interleukin-4 (IL)-4 in proliferating CD4+ T cells were assessed by flow cytometry. The proportion of cytokine-producing cells and proliferating cells in each division cycle was assessed using [5(and 6)-carboxyfluorescein diacetate, succinimidyl ester]-labelled CD4 +/- T cells.
Results. The proportion of IFN-gamma+ proliferating CD4+ T cells in each cell division cycle from extraglandular SS was increased in glandular SS patients compared glandular SS patients with controls (P < 0.05 similar to 0.01). The percentage of IFN-gamma single positive proliferating CD4+ T cells was greater in extraglandular SS patients (26.7 +/- 14.1%) compared with glandular SS (9.9 +/- 9.1%) (P < 0.01) and controls (9.4 +/- 5.8%) (P < 0.001). There was no significant difference in the percentages of IL-4+ proliferating CD4+ T cells among the groups. However, the proliferating response of CD4+ T cells was significantly decreased in extraglandular SS patients (percentage of proliferating cells 38.4 +/- 18.6%) compared with that in glandular SS patients (64.2 +/- 17.2%) (P < 0.05) and controls (63.1 +/- 10.6%) (P < 0.01).
Conclusions. CD4+ T cells from extraglandular SS patients may have a predisposition for entry into the IFN-gamma-producing effector pathway as a result of the stimulations. These results are helpful for understanding the immunological difference between glandular and extraglandular SS and the mechanisms of disease progression.
- リンク情報
- ID情報
-
- DOI : 10.1093/rheumatology/kei182
- ISSN : 1462-0324
- Web of Science ID : WOS:000236252400006